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ORIGINAL ARTICLE
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patients after hypothermic circulatory arrest
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Anne Vakkurid, Johanna Wennervirtad, Ulf-Håkan Stenmanb and Hannu Koistinenb
aDepartment of Cardiology, Helsinki University Hospital, Helsinki, Finland; bDepartment of Clinical Chemistry, University of Helsinki and
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ABSTRACT
The concentrations of several diagnostic markers have been found to increase dramatically in critically
ill patients with a severe disturbance of normal physiological homeostasis, without indication of the
diseases they are normally associated with. To prevent false diagnoses and inappropriate treatments
of critically ill patients, it is important that the markers aiding the selection of second-line treatments
are evaluated in such patients and not only in the healthy population and patients with diseases the
markers are associated with. The levels of trypsinogen isoenzymes, the trypsin inhibitor serine peptid-
ase inhibitor Kazal type 1 (SPINK1), hCG and hCGb, which are used as pancreatitis and cancer markers,
were analyzed by immunoassays from serum samples of 17 adult patients who have undergone sur-
gery of the ascending aorta during hypothermic circulatory arrest (HCA) with optional selective cere-
bral perfusion. Highly elevated levels of trypsinogen-1, -2 and -3, SPINK1 and hCGb were observed in
patients after HCA. This was accompanied by increased concentrations of S100b and NSE. In conclu-
sion, this study highlights the importance of critically evaluating the markers used for aiding selection
of second line of treatments in critically ill patients.
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Critically ill patients often suffer from generalized hypoper-
fusion and hypoxemia, which may lead to complications, a
systemic inflammation reaction, or even multiple-organ fail-
ure. Several markers, such as S100b and NSE for brain dam-
age, are used to guide treatment [1]. However, the levels of
some diagnostic markers, like pancreatitis markers lipase
and amylase, have been found to increase dramatically in
critically ill patients, without indication of the diseases they
are normally associated with [2,3]. The pancreas also produ-
ces several other proteins that are useful as diagnostic
markers, but have not been evaluated during critical illness.
These include different trypsinogen-isoenzymes, i.e. trypsi-
nogens-1, -2 and -3, and serine peptidase inhibitor Kazal
type 1 [SPINK1, also called tumor-associated trypsin inhibi-
tor (TATI) and pancreatic secretory trypsin inhibitor
(PSTI)] [4]. In acute pancreatitis the circulating levels of
these proteins are increased, making them useful as diagnos-
tic markers. Especially trypsinogen-2 and the complex of its
activated form, trypsin-2, with a1-antitrypsin (i.e. trypsin-
2–API) have been found to accurately predict severe acute
pancreatitis already at admission [5]. In addition to pancrea-
titis, the expression of trypsin(ogen)s and SPINK1 are
increased in several cancers, including pancreatic and
ovarian cancers, and hepatocellular and cholangiocarcino-
mas, where they may also have a cancer-promoting role
[4,6]. Pancreatic cancer is also associated with increased cir-
culating levels of human chorionic gonadotropin (hCG)
b-subunit (hCGb), which is produced in many non-tropho-
blastic tumors and elevated levels of which are associated
with adverse prognosis [7]. Here we report highly elevated
levels of trypsinogen-1, -2 and -3, SPINK1 and hCGb in
patients who have undergone surgery of the ascending aorta
during hypothermic circulatory arrest (HCA).
Materials and methods
In this prospective, single-center cohort study, we recruited
17 adult patients (38–75 years of age, mean± SD,
59 ± 10 years; 11 males and 6 females) who underwent elect-
ive (n¼ 10, 59%) or emergency (n¼ 7, 41%) surgery during
cardiopulmonary bypass for aortic dissection (n¼ 10, 59%)
or aneurysm (n¼ 7, 41%), and from whom serum and
plasma samples were collected before the operation and 1,
2, 3, and 5–7 d after the operation. For some of the patients,
samples were also available 8–10 d after the operation. All
patients were operated under HCA, with optional selective
cerebral perfusion. The patients were fully anticoagulated
with heparin during the operation and the effect of heparin
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was reversed with protamine in the end of the operation.
Patients with a preoperative neurological disease or symp-
toms were excluded. Twelve (71%) patients were classified
as having a good postoperative primary neurological out-
come as they survived the monitoring period with no sig-
nificant neurological complications, while five had a poor
outcome, defined by the appearance of new neurological
symptoms or lesions on a brain CT scan, or operative death.
Mild neurological complications were not classified as a
poor outcome. The monitoring period lasted from the pre-
operative stage (moments before anesthesia and intubation)
until extubation in the intensive care unit, or up to 48 h
after surgery. All participants, or next of kin, gave their
written informed consent. The study was approved by the
Helsinki University Hospital Ethics Committee (HUS 133/
E6/07).
The concentrations of trypsin(ogen)-1, -2 and -3 [8,9],
trypsin-2–API [10], SPINK1 [11] and hCG and hCGb [12]
were determined as described using in-house immuno-
fluorometric assays (IFMAs). The trypsin(ogen)-assays
detect both pro-forms and active forms of trypsins. hCG
was determined by a commercial IFMA (AutoDelfia,
Perkin-Elmer Wallac, Turku, Finland). The limits of detec-
tion for trypsinogen, trypsin-2–API and SPINK1 assays are
<0.5 mg/l and intra- and inter-assay coefficients of variation
(CV) <15%. For hCG and hCGb assays the limits of detec-
tion are <2 pmol/l and the intra-assay CV <10% at concen-
trations above 10 pmol/l. SPINK1, trypsinogen-1 and -2,
trypsin-2–API and hCGb were analyzed within a week after
the collection of the follow-up samples of individual
patients. Trypsinogen-3 was analyzed in multiple batches,
the samples being stored at 20 C up to 9months. hCG
was analyzed in a single batch after a maximum of 1 year
9months storage at 20 C. In our experience, such storage
times should not have a significant effect on the marker lev-
els (unpublished and [8–12]).
Serum S100b, serum neuron-specific enolase (NSE),
plasma C-reactive protein (CRP) and plasma amylase were
measured in accredited hospital laboratory (HUSLAB,
Helsinki, Finland) immediately after the sampling, as part of
clinical routine. S100 and NSE were quantitated with elec-
trochemiluminometric assays on an automatic immunoana-
lyzer (Elecsys 2010, Roche Diagnostics, Mannheim,
Deutschland). Detection limit of the S100 assay is 0.005mg/l,
and intra-assay and inter-assay CVs <3% and <4%, respect-
ively, in the concentration range 0.092.6 mg/l. Detection
limit of the NSE assay is 0.05mg/l, and intra-assay and
inter-assay CVs are <3% and <4%, respectively, in the con-
centration range 2.6103 mg/l. CRP was quantitated with an
immunoturbidimetric method and amylase with an enzyme
Figure 1. Time course of the changes in concentrations of the markers after hypothermic circulatory arrest (median and interquartile range, n¼ 16–17 for days
0–7 and n¼ 8–9 for day 8–10, except for hCG n¼ 11 and 6, respectively). Day 0 is the baseline sample, collected right before anesthesia induction. Dashed lines
show the upper reference limit of the markers. The upper reference limit for hCG varies between 1 and 7 IU/l depending on age and gender (see Table 1). One
outlier value of trypsin-2–API has been removed.
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kinetic method on Roche Modular analyzer (Roche
Diagnostics, Basel, Switzerland). The detection limits are
0.12mg/l, <3U/l, respectively.
Wilcoxon signed-rank test was used to evaluate the dif-
ferences between baseline and maximal levels of the markers
and Mann–Whitney U test to evaluate differences in marker
levels between different groups (IBM SPSS Statistics version
24; IBM SPSS, Armonk, NY). Asymptotic (two-tailed) p val-
ues are reported. The values are reported as median, and, in
parenthesis, interquartile range (IQR).
Results
Significantly increased concentrations of trypsinogen-1, -2
and -3, trypsin-2–API, SPINK1 and hCGb were observed in
patients after HCA (Figure 1, Table 1). In all patients, the
SPINK1 concentrations increased rapidly after the first day,
reaching concentrations exceeding the upper reference limit
17-fold on average and in two patients (12%) over 50-fold.
The concentrations remained increased until the end of fol-
low-up at 810 d. Trypsinogen-1 and -3 concentrations
peaked 1 d after HCA, after which they normalized within
one day and started again to rise in 13 (76%) and 10 (59%)
cases, respectively, exceeding the levels observed on day one.
The concentrations of trypsinogen-2 and trypsin-2–API
complex showed a similar pattern, although the peak on day
one was less pronounced, if found at all. The hCGb levels
also increased, but mostly only after day three, when the
hCG levels tend to decrease. These changes were accompa-
nied by increased concentrations of S100b and NSE one day
after HCA. Often the S100b and NSE levels normalized
within a week after HCA. In all but one patient amylase lev-
els also increased. However, in 11 (65%) patients this hap-
pened only 2 d after the operation or later. Serum CRP
levels before and 3 d after the operation were available from
ten patients (59%) and indicate a dramatic increase from 7.5
(3.0–60) to 226 (140–303) mg/l (p¼ .005).
The baseline levels of NSE were higher in patients who
underwent emergency surgery (n¼ 7) than in elective cases
(n¼ 10) [15.3 (11.7–22.5) and 11.2 (9.6–12.2) mg/l, respect-
ively, p¼ .019]. Similarly, the maximum SPINK1 levels
during the follow-up were higher in patients who underwent
emergency operation [375 (109–778) and 95.4 (51.7–145)
mg/l, p¼ .010]. Otherwise, there were no differences between
the studied markers in these two groups of patients. The
levels of studied markers did not differ between the patients
who had good or poor postoperative primary neuro-
logical outcome.
Discussion
The reason for the increased levels of the studied markers
after aortic surgery and HCA, and whether they reflect any
specific clinical condition(s) is unknown. There are, how-
ever, several possible explanations. All patients in this study
underwent cardiopulmonary bypass and HCA, which lead
to transient global ischemia and may lead to multi-organ
failure with signs of neuronal, liver and kidney damage.
Several patients also presented with blood–brain barrier dys-
function, as suggested by increased circulating levels of NSE
and S100b, and with systemic inflammation or tissue dam-
age as suggested by an increase in CRP concentrations fol-
lowing the operation. Since the levels of SPINK1 in
circulation have been found to be strongly increased in
severe inflammation and tissue damage [13], it is likely that
inflammation and tissue destruction explain the observed
increase in SPINK1 concentrations to which extrapancreatic
expression, potentially from the liver, may contribute to.
The trypsinogen-1, -2 and -3 and SPINK1 peak concen-
trations were similar to those observed in acute pancreatitis
patients [14]. However, the patients in this study were not
reported to have pancreatitis, although this cannot be com-
pletely ruled out. This agrees with the very modest and
transient increase in amylase. Of note, amylase levels have
been found to be significantly elevated after coronary artery
bypass surgery [15] and in variety of other conditions. Since
the expression of trypsin-isoenzymes has been found not
only in the pancreas, but also in many other tissues, includ-
ing brain and biliary tract [6], disturbed function in these
may also affect the levels of these markers.
Especially the early fluctuation in levels of studied
markers may also be related to transient renal insufficiency
Table 1. The baseline and postoperative concentrations of the studied markers.
Baseline (day 0) Peak concentrationa p Valueb Upper ref.
median (n, IQR) median (IQR) baseline vs. max limitc
S100b (mg/l) 0.05 (17, 0.03–0.06) 0.23 (0.14–0.38) <.001 0.11
NSE (mg/l) 12 (17, 10–14) 44 (34–59) <.001 16
Amylase (U/l) 41 (17, 28–68) 113 (65–224) <.001 120
Trypsinogen-1 (mg/l) 33 (17, 18–42) 87 (52–243) .001 70
Trypsinogen-2 (mg/l) 27 (17, 14–40) 305 (85–597) <.001 90
Trypsinogen-3 (mg/l) 0.56 (16, 0.01–1.48) 3.7 (1.5–12.4) .004 1.2
Trypsin-2–API (mg/l)d 5.3 (16, 3.9–9.7) 34 (18–87) <.001 25
SPINK1 (mg/l) 11 (17, 9–19) 123 (83–362) <.001 16.2
hCG (IU/l) 0.23 (11, 0.14–0.52) 0.44 (0.13–0.82) .859 1–7e
hCGb (pmol/l) 0.54 (17, 0.41–0.85) 3.1 (2.1–8.3) <.001 2
aHighest observed concentrations during the follow-up period.
bWilcoxon signed-rank test, baseline vs. highest levels.
cUpper reference limits.
dOne outlier value of trypsin-2–API has been removed from analyses.
eUpper reference limit for hCG is 3 IU/l for women <50 years of age and 7 IU/l for those >50 years, and 1 IU/l for men <60 years and 2 IU/l for those
>60 years of age.
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and dialysis after the operation. Moreover, the patients suf-
fered significant loss of blood and received autologous and
homologous blood transfusions, which may cause some fluc-
tuations in the marker levels. However, the increase in
hCGb is difficult to explain. We have found that hCGb lev-
els may be elevated in pancreatic and biliary cancer and sev-
eral other cancers [6], but only rarely in acute pancreatitis.
The finding of elevated hCGb concentrations in men with-
out cancer is new. The source of this hormone subunit
remains to be established.
In this small descriptive study, we did not find any dif-
ferences in the markers regarding the primary neurological
outcome of the patients. However, the baseline levels of
NSE and maximal levels of SPINK1 during the follow-up
were higher in patients who underwent emergency surgery
as compared to elective cases. It is possible, although specu-
lative, that the emergency cases had more pronounced brain
hypoxia, which resulted in higher NSE levels. However,
higher SPINK1 levels are hard to explain, especially as there
was no difference in CRP levels.
In conclusion, our results highlight the importance of
critically evaluating the markers used for aiding selection of
second line of treatments in critically ill patients.
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